AVRO News and Press, AVROBIO Inc. From 05/05/21

AVROBIO's competing drug Fabrazyme received full approval, resulting in a 2-year delay for AVRO. However, there are silver linings here in the bad news. One of those is the current depressed price. For further details see: AVROBIO: Fabrazyme's Full Approval Changes Thing...

Gainers: Precipio (PRPO) +102%.Regional Health Properties (RHE) +94%.American Shared Hospital Services (AMS) +33%.Brooklyn ImmunoTherapeutics (BTX) +26%.Scully Royalty (SRL) +25%.Ocugen (OCGN) +23%.Top Ships (TOPS) +23%.Rezolute (RZLT) +20%.Milestone Scientific (MLSS) +19%.Ashford H...

Anticipates initiating registration trial with kidney biopsy endpoint in mid-2022 to support potential full approval of AVR-RD-01 as first-line therapy, subject to FDA discussion and agreement Two additional patients dosed in last two months in ongoing FAB-GT Phase 2 trial; pl...

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that two oral presentations and two posters featuring data from its pipeline of lysosomal disorder gene therapy programs wil...

AVROBIO Inc. (NASDAQ:AVRO) traded today at a new 52-week low of $9.99. Approximately 252,000 shares have changed hands today, as compared to an average 30-day volume of 613,000 shares. Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ...

AVROBIO (AVRO): Q4 GAAP EPS of -$0.73 beats by $0.17.As of Dec. 31, 2020, AVROBIO had $259.7 million in cash and cash equivalents, as compared to $187.0 million in cash and cash equivalents as of Dec. 31, 2019.Press Release For further details see: AVROBIO EPS beats by $0.17

100% kidney substrate reduction at 12 months post-gene therapy in the first patient dosed with the plato ® gene therapy platform in FAB-GT 1 trial for Fabry disease One new patient dosed and three new patients enrolled in Fabry disease clinical trial since Jan...

Today Bluebird bio ([[BLUE]] +7.5%) announced that the BB305 lentiviral vector was unlikely to be the reason for the case of acute myeloid leukemia which had forced the company to halt two clinical trials for sickle cell disease (“SCD”).Noting that the update has essen...

AVR-RD-04 is the third AVROBIO investigational gene therapy to receive orphan drug designation AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European...

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in three upcoming virtual investor conferences. ...